Clinical Trials
30 trialsCombination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast Cancer
City of Hope Medical Center
Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery
National Cancer Institute (NCI)
Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery
Mayo Clinic
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Cancer Insight, LLC
GW572016 and Trastuzumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2/Neu
Jonsson Comprehensive Cancer Center
Docetaxel, Carboplatin, Trastuzumab, and Lapatinib in Treating Patients With Early Stage Breast Cancer
Alliance for Clinical Trials in Oncology
Cyclophosphamide and Vaccine Therapy With or Without Trastuzumab in Treating Patients With Metastatic Breast Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Trastuzumab, Cyclophosphamide, and Vaccine Therapy in Treating Patients With High-Risk or Metastatic Breast Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
Memorial Sloan Kettering Cancer Center
Doxorubicin Hydrochloride Liposome, Cyclophosphamide, and Trastuzumab in Treating Patients With Stage IV Breast Cancer
University of Washington
Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer
Memorial Sloan Kettering Cancer Center
Capecitabine, Vinorelbine, and Trastuzumab in Treating Patients With Metastatic Breast Cancer
Alliance for Clinical Trials in Oncology
Gefitinib, Trastuzumab, and Docetaxel in Treating Patients With Metastatic Breast Cancer
City of Hope Medical Center
Combination Chemotherapy With or Without Trastuzumab Followed By an Autologous Stem Cell Transplant and Radiation Therapy in Treating Patients With Stage III or Stage IV Breast Cancer
City of Hope Medical Center
Agatolimod and Trastuzumab in Treating Patients With Locally Advanced or Metastatic Breast Cancer
Ohio State University Comprehensive Cancer Center
Vorinostat and Trastuzumab in Treating Patients With Metastatic or Locally Recurrent Breast Cancer
National Cancer Institute (NCI)
Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer
National Cancer Institute (NCI)
Trastuzumab and Interleukin-2 in Treating Patients With Metastatic Breast Cancer
National Cancer Institute (NCI)
Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors
National Cancer Institute (NCI)
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
National Cancer Institute (NCI)
Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer
National Cancer Institute (NCI)
Trastuzumab and Flavopiridol in Treating Patients With Metastatic Breast Cancer
National Cancer Institute (NCI)
Trastuzumab and Gefitinib in Treating Patients With Metastatic Breast Cancer
National Cancer Institute (NCI)
T-Cell Response in Patients Receiving Trastuzumab and/or Chemotherapy for HER2-Positive Solid Tumors
Jonsson Comprehensive Cancer Center
Lonafarnib, Trastuzumab, and Paclitaxel in Treating Patients With HER2/Neu-Overexpressing Stage IIIB, Stage IIIC, or Stage IV Breast Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Tipifarnib Plus Trastuzumab in Treating Patients With Metastatic Breast Cancer
The University of Texas Health Science Center at San Antonio
Monoclonal Antibody Plus Chemotherapy in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2
National Institutes of Health Clinical Center (CC)
Trastuzumab and Pertuzumab in Treating Patients With Unresectable Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Trastuzumab
National Institutes of Health Clinical Center (CC)